Prostate Cancer - Results from #26220

Abiraterone acetate: Oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer - Abstract March 15, 2012

Improvement in prostate cancer survival over time: A 20-year analysis - Abstract March 15, 2012

Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy - Abstract March 14, 2012

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy - Abstract March 14, 2012

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer - Abstract March 14, 2012

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer - Abstract March 14, 2012

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): An observational study in a single institution - Abstract March 14, 2012

CD10 is inversely associated with nuclear factor-Kappa B and predicts biochemical recurrence after radical prostatectomy - Abstract March 13, 2012

Imaging in prostate cancer staging: Present role and future perspectives - Abstract March 13, 2012

Effects of physical activity on cancer risk and disease progression after cancer diagnosis - Abstract March 13, 2012

Third-generation salvage cryotherapy for radiorecurrent prostate cancer: A centre's experience - Abstract March 13, 2012

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer - Abstract March 13, 2012

High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: A 7-year experience - Abstract March 12, 2012

Patients and partners lack knowledge of androgen deprivation therapy side effects - Abstract March 12, 2012

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial - Abstract March 12, 2012

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy - Abstract March 12, 2012

Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: A systematic review of the literature - Abstract March 12, 2012

Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: Outcomes of 55Gy in 16 fractions at 3.4Gy per fraction - Abstract March 9, 2012

Temporal changes in quality of life after prostate carcinoma - Abstract March 9, 2012

Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer - Abstract March 9, 2012

Page 1312 of 1437